Innovation | Driving Breakthroughs in Cancer Diagnosis & Prognosis

알림

Because it is difficult to determine the metastasis-status, which is a factor in determining whether to remove lymph-nodes, decisions are often made based on the doctor's experience. If lymph-nodes that do not need to be removed are removed, metabolic-waste is not separated, causing serious edema, which significantly reduces the patient's quality of life. AiAlpa-Platform can predict metastasis-rates in real-time during surgery (Prediction-accuracy/F1-Score: 90%), preventing the removal of normal lymph-nodes.

HRD gene-test is a test that is performed to determine whether ovarian cancer patients should receive chemotherapy, but the cost of the test (7,000 dollars) is astronomically high. In addition, this test must be paid separately from the pathology-test, so the total cost including all tests and treatments is beyond what the patient can afford. Using AiAlpa-Platform (Prediction-accuracy/F1-Score: 90%), the results of the HRD gene-test can be predicted based on the pathology test image. This can innovatively reduce the financial burden on patients.

AiAlpa-Platform completely blocks the leakage of sensitive information such as patient identity and medical history.

AiAlpa-Platform deletes all personal information existing in digital pathology slide images through its own technology and transmits only image information for pathology diagnosis to the AI analysis server.

The service is provided in a hybrid manner(On-premise, Cloud), and if the institution so desires, the service is provided in an On-premise manner to prevent patient data from being leaked to the outside.

Because it is difficult to determine the metastasis-status, which is a factor in determining whether to remove lymph-nodes, decisions are often made based on the doctor's experience. If lymph-nodes that do not need to be removed are removed, metabolic-waste is not separated, causing serious edema, which significantly reduces the patient's quality of life. AiAlpa-Platform can predict metastasis-rates in real-time during surgery (Prediction-accuracy/F1-Score: 90%), preventing the removal of normal lymph-nodes.

HRD gene-test is a test that is performed to determine whether ovarian cancer patients should receive chemotherapy, but the cost of the test (7,000 dollars) is astronomically high. In addition, this test must be paid separately from the pathology-test, so the total cost including all tests and treatments is beyond what the patient can afford. Using AiAlpa-Platform (Prediction-accuracy/F1-Score: 90%), the results of the HRD gene-test can be predicted based on the pathology test image. This can innovatively reduce the financial burden on patients.

AiAlpa-Platform completely blocks the leakage of sensitive information
such as patient identity and medical history.

AiAlpa-Platform deletes all personal information existing in digital pathology slide images
through its own technology and transmits only image information
for pathology diagnosis to the AI analysis server.

The service is provided in a hybrid manner(On-premise, Cloud), and
if the institution so desires, the service is provided in an On-premise manner
to prevent patient data from being leaked to the outside.